Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT06942416
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer
Phase II, Single-Arm, Multicenter Clinical Study of Iparomlimab and Tuvonralimab in Combination With Paclitaxel Plus Cisplatin/Carboplatin and Radiotherapy for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer
Sponsor: Shandong Cancer Hospital and Institute
Updated 1 time since 2025 Last updated: Apr 16, 2025 Started: Feb 28, 2025 Primary completion: Jul 31, 2026 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06942416, this PHASE2 trial focuses on Cervical Cancer and Neoplasm Recurrence, Local and remains actively recruiting participants. Sponsored by Shandong Cancer Hospital and Institute, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shandong Cancer Hospital and Institute
Data source: Shandong Cancer Hospital and Institute
For direct contact, visit the study record on ClinicalTrials.gov .